Abstracts tagged "Synovitis"

Abstract Number: 1906 • ACR Convergence 2022
Bile Acid Profile Is Associated to Synovitis in Knee Osteoarthritis
Roxana Coras¹, Jessica Murillo Saich², Michal Hose Sanchez³, Anne Quan³, Emily Gentry¹, Pieter Dorrestein¹, Nancy Lane⁴ and Monica Guma⁵, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³VA San Diego Healthcare System, San Diego, CA, ⁴University of California Davis, Hillsborough, CA, ⁵Division of Rheumatology, Allergy, and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Increasing evidence indicates that low grade systemic and local inflammation contributes to osteoarthritis (OA) progression. Bioactive lipid mediators are signaling molecules involved in inflammatory…
Abstract Number: 0019 • ACR Convergence 2022
Bacterial Peptidoglycan in Synovial Tissue at Time of Total Knee Arthroplasty Is Associated with Inflammatory Synovitis and Younger Patient Age
Meaghan Holub¹, Amanda Wahhab², Joseph Rouse², Brandon Jutras³, Klemen Strle⁴, Adam Edelstein⁵ and Robert Lochhead⁶, ¹Central Michigan University College of Medicine, Mount Pleasant, MI, ²Medical College of Wisconsin, Milwaukee, WI, ³Virginia Tech, Blacksburg, VA, ⁴Wadsworth Center, Albany, NY, ⁵Northwestern Medicine, Chicago, IL, ⁶Medical College of Wisconsin, Germantown, WI
Background/Purpose: Peptidoglycan (PG) is a bacterial cell wall component that is known to induce innate immune responses. PG has been identified as a driver of…
Abstract Number: 1969 • ACR Convergence 2022
The Potential Diagnostic Value of C-X-C Motif Chemokine 13 (CXCL13) in Seronegative Arthritis
Silvia Piantoni¹, Fabrizio Angeli¹, Francesca Regola², Franco Franceschini² and Paolo Airò³, ¹Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ³Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy
Background/Purpose: The finding of circulating biomarkers in the field of chronic arthritis is still an unmet need, especially for the subgroup of seronegative arthritis [e.g.,…
Abstract Number: 0261 • ACR Convergence 2022
Machine Learning and Computational Pathology Can Reveal Synovial Pathotypes in Mice and Humans
Richard Bell¹, Matthew Brendel², Justin Xiang³, AMP RA/SLE Consortium¹, Edward DiCarlo¹, Jennifer Anolik⁴, Laura Donlin¹, Dana Orange⁵, Edward Schwarz⁴, Lionel Ivashkiv¹ and Fei Wang², ¹Hospital for Special Surgery, New York, NY, ²Weil Cornell Medical College, New York, NY, ³Horace Grant High School, New York, NY, ⁴University of Rochester Medical Center, Rochester, NY, ⁵The Rockefeller University, New York, NY
Background/Purpose: Synovial pathotyping is a critical step in understanding the etiology of inflammatory arthritis as different pathotypes have differential response to therapy. Determining these pathotypes…
Abstract Number: 1971 • ACR Convergence 2022
Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment
Sascha Heckert¹, Sytske Anne Bergstra², Yvonne Goekoop-Ruiterman³, Melek Guler-Yuksel⁴, Willem Lems⁵, Xanthe Matthijssen⁶, Maikel Van Oosterhout⁷, Tom Huizinga⁶ and CF Allaart⁶, ¹Leiden University Medical Centre, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³HagaZiekenhuis, The Hague, Netherlands, ⁴Maasstad ziekenhuis, Rotterdam, Netherlands, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands
Background/Purpose: In Rheumatoid Arthritis (RA), both systemic and local disease activity have been shown to be associated with joint damage progression. Earlier we showed that…
Abstract Number: 0404 • ACR Convergence 2022
Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial
Raphael Micheroli¹, Tim Killeen², Hyejin Jo³, Kenneth Kwok³, Bassel Elzorkany⁴, Caroline Ospelt⁵, Adrian Ciurea⁶ and Michael Nissen⁷, ¹University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ²Pfizer Ltd, Tadworth, Switzerland, ³Pfizer Inc, New York, NY, ⁴Department of Rheumatology, Cairo University, Cairo, Egypt, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶University Hospital Zurich, Zürich, Switzerland, ⁷Hopitaux Universitaires de Genève, Geneva, Switzerland
Background/Purpose: Sites of peripheral joint and enthesitis involvement in AS vary. Tofacitinib is an oral Janus kinase inhibitor for the treatment of AS. Differential site-specific…
Abstract Number: 1979 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
Costantino Pitzalis¹, rebecca hands², Swamy Venuturupalli³, Ami Ben-artzi⁴, Eric Ruderman⁵, Harris Perlman⁶, Arthur Mandelin⁵, Mara Leach⁷, Addison Hasselbach⁷, Bonnie Abbruzzese⁷, Rachael Hershey⁷, Beth Potter⁷, Jessica Fitzpatrick⁷, Aaron Thornton⁷, Michael Blue⁷, Jonathan Graf⁸, David Ralph⁷ and Michael Rosol⁷, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Navidea Biopharmaceuticals, Dublin, OH, ⁸Ucsf, San Francisco, CA
Background/Purpose: The primary objective of this study is to assess the relationship between joint-specific Tc99m tilmanocept (TIL) uptake values and the pathobiology of RA-involved joint…
Abstract Number: 0500 • ACR Convergence 2022
T Cell and Macrophage Synergy Drive Inflammatory Synovial Fibroblasts in Rheumatoid but Not Psoriatic Arthritis
Achilleas Floudas¹, conor Smith², Orla Tynan³, Nuno Neto⁴, Krishna Vinod⁵, Sarah Wade⁶, Megan Hanlon⁷, Clare Cunningham⁴, Viviana Marzaioli⁸, Mary Canavan⁹, Jean Fletcher³, Ronan Mullan¹⁰, Suzanne Cole¹¹, Ling-Yang Hao¹², Michael Monaghan⁴, Sunil Nagpal¹³, Douglas Veale¹⁴ and Ursula Fearon⁴, ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ²bTrinity College Dublin, Dublin, Ireland, ³Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Janssen, Spring House, PA, ⁶Trinity Biomedical Sciences Institute, Wexford, Ireland, ⁷Molecular Rheumatology, Dublin, Ireland, ⁸Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁹Trinity College, Dublin, Ireland, ¹⁰Tallaght University Hospital, Dublin, Ireland, ¹¹Rheumatic Disease Associates, Warminster, PA, ¹²Janssen Research and Development, LLC, Spring House, PA, ¹³Janssen Research, Collegeville, PA, ¹⁴St. Vincent's University Hospital, Blackrock, Dublin, Ireland
Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are common autoimmune diseases of unknown aetiology characterised by complex synovial pathology with a detrimental effect on the…
Abstract Number: 2141 • ACR Convergence 2022
How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study
Maria-Antonietta D'Agostino¹, Philip G Conaghan², Corine Gaillez³, Esperanza Naredo⁴, Peter mandl⁵, Philippe Carron⁶, Ladislav Šenolt⁷, Javier Eduardo Rosa⁸, Alejandra Lopez Rdz⁹, Punit Goyanka¹⁰, Braja Gopal Sahoo¹⁰, Weibin Bao¹¹, Georg Schett¹² and Maarten Boers¹³, ¹Catholic University of Sacred Heart, Roma, Italy, ²University of Leeds, Leeds, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Dermatológico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, India, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹²Universitätsklinikum Erlangen, Erlangen, Germany, ¹³Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
Background/Purpose: Power Doppler ultrasound (PDUS) allows the visualization of morphological and inflammatory changes of the synovium. The ULTIMATE study (NCT02662985) was the first large, randomized,…
Abstract Number: 0501 • ACR Convergence 2022
Single-molecule Spatial Transcriptomic Analysis Reveals Distinct Cellular Networks in Rheumatoid Arthritis Synovia
Roopa Madhu¹, Kartik Bhamidipati¹, Nghia Millard², Michelle Curtis², Ye Cui³, Youngmi Kim³, Ellen Gravallese⁴, Soumya Raychaudhuri¹, Michael Brenner⁴, ilya Korsunsky¹ and Kevin Wei⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Boston, MA, ³Nanostring Technologies Inc., Seattle, WA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic joint inflammation in rheumatoid arthritis (RA) arises from the interactions of many cell types. Single-cell transcriptomic profiling of RA joints has identified novel…
Abstract Number: 2166 • ACR Convergence 2022
Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments
Eric Schwender¹, Dylan Hansen², Wendy Stevens², Laura Ross³, Nava Ferdowsi², Susanna Proudman⁴, Jenny Walker⁵, Jo Sahhar⁶, Gene-Siew Ngian⁷, Lauren Host⁸, Gabor Major⁹, Mandana Nikpour¹⁰ and Kathleen Morrisroe², ¹Royal College of Surgeons, Dublin, Ireland, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ⁴Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁵Royal Adelaide Hospital, Adelaide, Australia, ⁶Monash Health, Melbourne, Australia, ⁷Melbourne Health, Northcote, Australia, ⁸Fiona Stanley Hospital, London, United Kingdom, ⁹Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, ¹⁰The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: To characterise a cohort of Australian scleroderma patients with inflammatory arthritis including patient characteristics, autoantibody profile, therapy and impact on function and quality of…
Abstract Number: 0554 • ACR Convergence 2022
Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Clinical Onset
Megan Hanlon¹, Mary Canavan², conor Smith³, Achilleas Floudas⁴, Nuno Neto⁵, Qingxuan Song⁶, Phil Gallagher⁷, Ronan Mullan⁸, Conor Hurson⁹, Barry Moran⁵, Michael Monaghan⁵, Sunil Nagpal¹⁰, Douglas Veale¹¹ and Ursula Fearon⁵, ¹Molecular Rheumatology, Dublin, Ireland, ²Trinity College, Dublin, Ireland, ³bTrinity College Dublin, Dublin, Ireland, ⁴Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁵Trinity College Dublin, Dublin, Ireland, ⁶Janssen Research and Development, LLC, Spring House, PA, ⁷St Vincent's University Hospital, Dublin, Ireland, ⁸Tallaght University Hospital, Dublin, Ireland, ⁹St Vincents University Hospital, Dublin, Ireland, ¹⁰Janssen Research, Collegeville, PA, ¹¹St. Vincent's University Hospital, Blackrock, Dublin, Ireland
Background/Purpose: Synovial-tissue macrophages significantly contribute to Rheumatoid Arthritis, yet the precise nature/function of macrophage subsets within the inflamed joint remains unexplored. Here we explore the…
Abstract Number: 0619 • ACR Convergence 2022
Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons
Selina Ohl¹, Klaus Frommer², Markus Rickert³, Stefan Rehart⁴, Ulf Müller-Ladner⁵ and Elena Neumann⁶, ¹Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ²Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ³Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, Gießen, Germany, ⁴Agaplesion Markus Hospital, Dpt of Orthopaedics and Trauma Surgery, Frankfurt, Germany, ⁵JLU Campus KK, Bad Nauheim, Germany, ⁶JLU Gießen, Campus Kerckhoff, Bad Nauheim, Germany
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose inflammatory processes in the synovium lead to the destruction of cartilage and bone. Although there…
Abstract Number: 0758 • ACR Convergence 2022
Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study
Azin Rouhi¹, Shahin Jamal², Marie Hudson³, Janet Pope⁴, Janet Roberts⁵, Alexandra Ladouceur³, Sara Hewitt⁶ and Carrie Ye¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Dalhousie University, Halifax, NS, Canada, ⁶Western University, London, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have shown great promise in the treatment of different malignancies. The use of ICIs has been associated with toxicities that…
Abstract Number: 0776 • ACR Convergence 2022
Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey
Sebastian Bruera¹, Maria Suarez-Almazor² and mar Riveiro-Barciela³, ¹Baylor College of Medicine, Houston, TX, ²MD Anderson Cancer Center, Houston, TX, ³Hospital Universitari Vall d'Hebron, Barcelona, Spain
Background/Purpose: The management of inflammatory arthritis related to immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICI) is challenging. Arthritis can become chronic and require…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].